SELLAS Life Sciences (SLS) Change in Acquisitions & Divestments (2013)

SELLAS Life Sciences (SLS) reported Change in Acquisitions & Divestments of $2.5 million for Q4 2013, up 209.46% on a QoQ basis from $814000.0 in Q3 2013.

SELLAS Life Sciences (SLS) has 1 years of Change in Acquisitions & Divestments data on file, last reported at $2.5 million in Q4 2013.

  • Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $2.5 million in Q4 2013, while the trailing twelve-month figure through Dec 2014 was $3.3 million (changed 0.0% YoY) and the FY2013 annual result came in at $3.9 million, changed N/A from the prior year.
  • Change in Acquisitions & Divestments improved to $2.5 million in Q4 2013 per SLS's latest filing, from $814000.0 in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $2.5 million in Q4 2013 and bottomed at $814000.0 in Q3 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 SELLAS Life Sciences 1.61 Bn 1.61 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2013 2.52 Mn
Dec 31, 2013 2.52 Mn
Sep 30, 2013 814,000.00
Sep 30, 2013 814,000.00